TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05994365

Intervention type: DRUG
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
Study: NCT05490407

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
Study: NCT06206642

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
Study: NCT05877573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg,d1,q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-term radiotherapy
Description: 25Gy/5Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 135mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1200mg/m2 d1-14 q3w
Study: NCT06252727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Given PO
Study: NCT05998005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Face Training Program
Description: First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: First Face Training Program
Description: First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
Study: NCT06630377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOS
Description: During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Study: NCT06631690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic and functional balance tests
Description: Isokinetic and functional balance tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic and functional balance tests
Description: Isokinetic and functional balance tests
Study: NCT06628440

Intervention type: OTHER
Intervention: oral condition assessment tool
Description: Use of the Mat assessment tool by a nurse on the participant
Study: NCT06178315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac plexus block
Description: Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Celiac plexus will not be performed in this arm.
Study: NCT05710744

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shared decision making tip sheet
Description: Physicians will view tip sheets containing best practices for shared decision making with diverse families.
Study: NCT05937906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I - Mirdametinib - Level 1
Description: Mirdametinib 4 mg twice/day for 7 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II - Mirdametinib
Description: For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I - Mirdametinib - Level 2
Description: Mirdametinib 4 mg twice/day for 14 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I - Mirdametinib - Level 3
Description: Mirdametinib 6 mg twice/day for 7 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I - Mirdametinib - Level 4
Description: Mirdametinib 6 mg twice/day for 14 days per cycle
Study: NCT04968132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent opioid reduction and pain management pathway
Description: Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard perioperative care, surgical treatment, and pain medications.
Study: NCT05358717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to PTC518 will be administered per schedule specified in the arm.
Study: NCT04747548

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kurbo Only
Description: Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kurbo + PolyRules!
Description: In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
Study: NCT06050863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: silk fibroin
Description: silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidin
Description: chlorhexidine is used

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combination of silk fibroin and chlorhexidine
Description: combination of silk fibroin and chlorhexidine is used
Study: NCT04703660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical mobilization
Description: 3 types of cervical mobilization at the level of C 5- 6

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical mobilization
Description: 3 types of cervical mobilization at the level of C 5- 6

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical mobilization
Description: 3 types of cervical mobilization at the level of C 5- 6
Study: NCT05457491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human platelet extract (cosmetic product)
Description: A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vanicream Gentle Facial Cleanser
Description: A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
Study: NCT06177054

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rotation guided by ultrasound
Description: Instruction to avoid areas with hyperechogenicity - after two weeks observation
Study: NCT05335850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isha Kriya
Description: Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nadi Shuddhi
Description: Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
Study: NCT04875039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Dexamethasone
Description: A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
Study: NCT05239897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
Study: NCT06180837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension Intervention
Description: Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
Study: NCT05041257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
Study: NCT05917587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: 12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
Study: NCT04395001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Therapy (CBT)
Description: The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Therapy (CBT)
Description: The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-delivered Motivational Interviewing
Description: Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
Study: NCT04775797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-836
Description: Capsules or Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules of Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-836
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-836
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-836
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-836
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue
Description: Tablets
Study: NCT05335850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nada Yoga
Description: Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Daily Activity
Description: Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
Study: NCT05457491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EltaMD UV Daily Broad-Spectrum SPF 40
Description: A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EltaMD PM Therapy Facial Moisturizer
Description: A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vanicream Lite Lotion
Description: Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
Study: NCT05447897

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Group Interviews
Description: One time interview, 60-90 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: Stakeholder advisory group
Description: The team will meet with the stakeholder advisory group four times for 1-2 hours each
Study: NCT05291325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3L PEG + Linaclotide
Description: Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L PEG
Description: Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG + Linaclotide
Description: Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
Study: NCT05751044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral/intervenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal chemotherapy
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study: NCT06557096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 MG
Description: Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
Study: NCT05746494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active anodal tDCS and sham tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: active anodal tDCS and sham tDCS
Study: NCT06460519

Intervention type: OTHER
Intervention: Non-invasive blood pressure measurements
Description: Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
Study: NCT06162351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038
Description: Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death.
Study: NCT06314594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention treatment
Description: Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy
Study: NCT05245097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tango Belt
Description: The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
Study: NCT05131919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
Study: NCT06141057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix M with RH5.1
Description: 50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix M with RH5.1
Description: 50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.